tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Photocure ASA Achieves Record Revenues and Expands Market Presence

Story Highlights
Photocure ASA Achieves Record Revenues and Expands Market Presence

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Photocure ASA ( (PHCUF) ) has shared an announcement.

Photocure ASA reported record revenues for its Hexvix®/Cysview® products in the second quarter of 2025, driven by strong performance in the U.S. market and increased adoption of blue light cystoscopy technology. The company expects continued revenue growth and EBITDA improvement, with strategic expansions and partnerships, including a promising collaboration with Richard Wolf and a potential milestone from a license agreement with Asieris for Cevira in China.

More about Photocure ASA

Photocure ASA, known as The Bladder Cancer Company, specializes in providing transformative solutions to enhance the lives of bladder cancer patients. Their unique technology, which causes cancer cells to glow bright pink, has improved health outcomes globally. The company is headquartered in Oslo, Norway, and is listed on the Oslo Stock Exchange.

Average Trading Volume: 47,792

Current Market Cap: NOK1.68B

For an in-depth examination of PHCUF stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1